<code id='E294065475'></code><style id='E294065475'></style>
    • <acronym id='E294065475'></acronym>
      <center id='E294065475'><center id='E294065475'><tfoot id='E294065475'></tfoot></center><abbr id='E294065475'><dir id='E294065475'><tfoot id='E294065475'></tfoot><noframes id='E294065475'>

    • <optgroup id='E294065475'><strike id='E294065475'><sup id='E294065475'></sup></strike><code id='E294065475'></code></optgroup>
        1. <b id='E294065475'><label id='E294065475'><select id='E294065475'><dt id='E294065475'><span id='E294065475'></span></dt></select></label></b><u id='E294065475'></u>
          <i id='E294065475'><strike id='E294065475'><tt id='E294065475'><pre id='E294065475'></pre></tt></strike></i>

          
          WSS
          ASH19 CAR-T
          Victor Segura Ibarra and Rita Serda, Ph.D., NCI, NIH

          The Food and Drug Administration on Wednesday approved a futuristic new approach to treating cancer, clearing a Novartis therapy that has produced unprecedented results in patients with a rare and deadly cancer. The price tag: $475,000 for a course of treatment.

          That sounds staggering to many patients — but it’s far less than analysts expected.

          advertisement

          The therapy, called a CAR-T, is made by harvesting patients’ white blood cells and rewiring them to home in on tumors. Novartis’s product is the first CAR-T therapy to come before the FDA, leading a pack of novel treatments that promise to change the standard of care for certain aggressive blood cancers.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          entertainment